Literature DB >> 12527813

Maurotoxin: a potent inhibitor of intermediate conductance Ca2+-activated potassium channels.

N A Castle1, D O London, C Creech, Z Fajloun, J W Stocker, J-M Sabatier.   

Abstract

Maurotoxin, a 34-amino acid toxin from Scorpio maurus scorpion venom, was examined for its ability to inhibit cloned human SK (SK1, SK2, and SK3), IK1, and Slo1 calcium-activated potassium (K(Ca)) channels. Maurotoxin was found to produce a potent inhibition of Ca(2+)-activated (86)Rb efflux (IC(50), 1.4 nM) and inwardly rectifying potassium currents (IC(50), 1 nM) in CHO cells stably expressing IK1. In contrast, maurotoxin produced no inhibition of SK1, SK2, and SK3 small-conductance or Slo1 large-conductance K(Ca) channels at up to 1 microM in physiologically relevant ionic strength buffers. Maurotoxin did inhibit (86)Rb efflux (IC(50), 45 nM) through, and (125)I-apamin binding (K(i), 10 nM) to SK channels in low ionic strength buffers (i.e., 18 mM sodium, 250 mM sucrose), which is consistent with previous reports of inhibition of apamin binding to brain synaptosomes. Under similar low ionic strength conditions, the potency for maurotoxin inhibition of IK1 increased by approximately 100-fold (IC(50), 14 pM). In agreement with its ability to inhibit recombinant IK1 potassium channels, maurotoxin was found to potently inhibit the Gardos channel in human red blood cells and to inhibit the K(Ca) in activated human T lymphocytes without affecting the voltage-gated potassium current encoded by Kv1.3. Maurotoxin also did not inhibit Kv1.1 potassium channels but potently blocked Kv1.2 (IC(50), 0.1 nM). Mutation analysis indicates that similar amino acid residues contribute to the blocking activity of both IK1 and Kv1.2. The results from this study show that maurotoxin is a potent inhibitor of the IK1 subclass of K(Ca) potassium channels and may serve as a useful tool for further defining the physiological role of this channel subtype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527813     DOI: 10.1124/mol.63.2.409

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  35 in total

Review 1.  K+ channels as targets for specific immunomodulation.

Authors:  K George Chandy; Heike Wulff; Christine Beeton; Michael Pennington; George A Gutman; Michael D Cahalan
Journal:  Trends Pharmacol Sci       Date:  2004-05       Impact factor: 14.819

2.  Ca2+-activated K channels in parotid acinar cells: The functional basis for the hyperpolarized activation of BK channels.

Authors:  Victor G Romanenko; Jill Thompson; Ted Begenisich
Journal:  Channels (Austin)       Date:  2010-07-28       Impact factor: 2.581

3.  Small-Conductance Ca2+-Activated Potassium Channels Negatively Regulate Aldosterone Secretion in Human Adrenocortical Cells.

Authors:  Tingting Yang; Hai-Liang Zhang; Qingnan Liang; Yingtang Shi; Yan-Ai Mei; Paula Q Barrett; Changlong Hu
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

Review 4.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

5.  Inhibition of EDHF by two new combinations of K+-channel inhibitors in rat isolated mesenteric arteries.

Authors:  Jane M Hinton; Philip D Langton
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

6.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

7.  Calcium-dependent potassium channels control proliferation of cardiac progenitor cells and bone marrow-derived mesenchymal stem cells.

Authors:  Patrick Vigneault; Patrice Naud; Xiaoyan Qi; Jiening Xiao; Louis Villeneuve; Darryl R Davis; Stanley Nattel
Journal:  J Physiol       Date:  2018-05-05       Impact factor: 5.182

8.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.

Authors:  Heike Wulff; Neil A Castle
Journal:  Expert Rev Clin Pharmacol       Date:  2010-05       Impact factor: 5.045

9.  Contribution of Kv1.2 voltage-gated potassium channel to D2 autoreceptor regulation of axonal dopamine overflow.

Authors:  Stephanie Fulton; Dominic Thibault; Jose A Mendez; Nicolas Lahaie; Emanuele Tirotta; Emiliana Borrelli; Michel Bouvier; Bruce L Tempel; Louis-Eric Trudeau
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

Review 10.  Molecular and cellular basis of small--and intermediate-conductance, calcium-activated potassium channel function in the brain.

Authors:  P Pedarzani; M Stocker
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.